Both groups had significant decreases in number of incontinent episodes (59% for treatment, 40% for placebo) with no significant difference between groups.

• 两组的尿失禁次数都显著地下降（治疗组为59%25、安慰剂组为40%25），而两组之间并没有什麽差异；